IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive: In a phase I/II study, autologous DC vaccines were subcutaneously injected into CML-CP patients who did not achieve an adequate cytogenetic response after treatment with IFN-α or imatinib.